Smoldering Multiple Myeloma
Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder with a high risk of progression to multiple myeloma (MM) or amyloidosis. Of those with SMM, the risk of progression to MM is 10% per year in the first five years of the disease.1
SMM is characterized by abnormalities in plasma cells, causing them to produce too much of a specific protein that then builds up in the urine. This results in higher levels of the protein in the blood or urine, as well as an increase in the number of myeloma cells in the bone marrow.
OncoPep is advancing PVX-410, a novel therapeutic cancer vaccine that has the potential to address this unmet medical need. PVX-410 contains four proprietary peptides designed to specifically target MM cells, with the goal of "training" the immune system to recognize and attack the cancer cells before the cancer advances.
1 Kyle, RA et al Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia, (2010) 24 1121-1127